TY - JOUR
T1 - Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer
AU - Okamoto, Hiroshi
AU - Taniyama, Yusuke
AU - Sakurai, Tadashi
AU - Heishi, Takahiro
AU - Teshima, Jin
AU - Sato, Chiaki
AU - Maruyama, Shota
AU - Ito, Ken
AU - Onodera, Yu
AU - Konno-Kumagai, Takuro
AU - Ishida, Hirotaka
AU - Kamei, Takashi
N1 - Publisher Copyright:
© 2018, The Japan Esophageal Society and Springer Japan KK, part of Springer Nature.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Background: Recently, definitive chemoradiotherapy (dCRT) has become one of the essential treatment strategies for esophageal squamous cell carcinoma (ESCC) and has been especially gaining prevalence for cervical ESCC to preserve the larynx. Our department recently introduced dCRT concomitant with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for treating advanced cervical ESCC. This study aims to assess the safety and outcomes of DCF-R in patients with advanced cervical ESCC. Methods: We retrospectively assessed 11 patients with advanced cervical ESCC (clinical stage: II–IV, including T4b and/or M1 lymph node) who received DCF-R as the first-line treatment between December 2010 and February 2015. Results: Our patient cohort comprised 8 males and 3 females (median age 68 years; range 54–76 years). The pretreatment clinical stage included stage II (1), stage III (7), and stage IV (3) cases [including 3 patients with T4b (2 trachea and 1 thyroid) and 3 patients with M1 lymph node]. We attained complete response (CR) in 10 patients and stable disease in 1 patient. Of 10 patients with CR, 5 experienced recurrence and 5 continued exhibiting CR. Furthermore, grade 3 or more adverse events included leucopenia (91%), neutropenia (91%), febrile neutropenia (45%), and pharyngeal pain (55%). While the 2-year overall survival rate was 72%, the 2-year recurrent-free survival rate was 64%, respectively. Conclusions: DCF-R treatment for advanced cervical esophageal cancer could be completed by the careful administration; although a strong blood toxicity might occur, this treatment may provide the chance to obtain favorable prognosis with larynx preservation.
AB - Background: Recently, definitive chemoradiotherapy (dCRT) has become one of the essential treatment strategies for esophageal squamous cell carcinoma (ESCC) and has been especially gaining prevalence for cervical ESCC to preserve the larynx. Our department recently introduced dCRT concomitant with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for treating advanced cervical ESCC. This study aims to assess the safety and outcomes of DCF-R in patients with advanced cervical ESCC. Methods: We retrospectively assessed 11 patients with advanced cervical ESCC (clinical stage: II–IV, including T4b and/or M1 lymph node) who received DCF-R as the first-line treatment between December 2010 and February 2015. Results: Our patient cohort comprised 8 males and 3 females (median age 68 years; range 54–76 years). The pretreatment clinical stage included stage II (1), stage III (7), and stage IV (3) cases [including 3 patients with T4b (2 trachea and 1 thyroid) and 3 patients with M1 lymph node]. We attained complete response (CR) in 10 patients and stable disease in 1 patient. Of 10 patients with CR, 5 experienced recurrence and 5 continued exhibiting CR. Furthermore, grade 3 or more adverse events included leucopenia (91%), neutropenia (91%), febrile neutropenia (45%), and pharyngeal pain (55%). While the 2-year overall survival rate was 72%, the 2-year recurrent-free survival rate was 64%, respectively. Conclusions: DCF-R treatment for advanced cervical esophageal cancer could be completed by the careful administration; although a strong blood toxicity might occur, this treatment may provide the chance to obtain favorable prognosis with larynx preservation.
KW - 5-Fluorouracil
KW - Chemoradiotherapy
KW - Cisplatin
KW - Docetaxel
KW - Esophageal squamous cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85048567341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048567341&partnerID=8YFLogxK
U2 - 10.1007/s10388-018-0627-7
DO - 10.1007/s10388-018-0627-7
M3 - Article
C2 - 29948480
AN - SCOPUS:85048567341
VL - 15
SP - 281
EP - 285
JO - Esophagus
JF - Esophagus
SN - 1612-9059
IS - 4
ER -